Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy

Elizabeth R Hawkins, Reena R D’Souza, Astero Klampatsa Division of Cancer Therapeutics, The Institute of Cancer Research, London, UKCorrespondence: Astero KlampatsaThoracic Oncology Immunotherapy Group, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Su...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hawkins ER, D'Souza RR, Klampatsa A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	armored car t-cells immunotherapy tumor microenvironment solid tumors immunosuppression cell therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ebb64adc425b40b8aba3cb8d1d89150f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ebb64adc425b40b8aba3cb8d1d89150f
record_format	dspace
spelling	oai:doaj.org-article:ebb64adc425b40b8aba3cb8d1d89150f2021-12-02T14:39:09ZArmored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy1177-5491https://doaj.org/article/ebb64adc425b40b8aba3cb8d1d89150f2021-04-01T00:00:00Zhttps://www.dovepress.com/armored-car-t-cells-the-next-chapter-in-t-cell-cancer-immunotherapy-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Elizabeth R Hawkins, Reena R D’Souza, Astero Klampatsa Division of Cancer Therapeutics, The Institute of Cancer Research, London, UKCorrespondence: Astero KlampatsaThoracic Oncology Immunotherapy Group, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UKTel +44 208 722 4090Email astero.klampatsa@icr.ac.ukAbstract: Chimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic receptor which redirects effector function to the tumor, to improve efficacy and reduce toxicities associated with conventional treatments, such as radiotherapy and chemotherapy. This approach has proved effective in treating hematological malignancies; however, the same effects have not been observed in solid tumors. The immunosuppressive tumor microenvironment (TME) creates a significant barrier to solid tumor efficacy and reduces the anti-cancer activity of endogenous tumor-resident immune cells, enabling cancer progression. In recent years, researchers have attempted to enhance CAR T-cell function in the TME by engineering the cells to express various proteins alongside the CAR. Examples of this engineering include inducing CAR T-cells to secrete cytokines or express cytokine receptors to modulate the cytokine milieu of the TME. Alternatively, the CAR T-cell may secrete antibody-like proteins to target a range of tumor antigens. Collectively, these methods are termed armored CAR T-cell therapy, and in this review, we will discuss the range of armored CAR T-cell approaches which have been investigated to date.Keywords: armored CAR T-cells, immunotherapy, tumor microenvironment, solid tumors, immunosuppression, cell therapyHawkins ERD'Souza RRKlampatsa ADove Medical Pressarticlearmored car t-cellsimmunotherapytumor microenvironmentsolid tumorsimmunosuppressioncell therapyMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 95-105 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	armored car t-cells immunotherapy tumor microenvironment solid tumors immunosuppression cell therapy Medicine (General) R5-920
spellingShingle	armored car t-cells immunotherapy tumor microenvironment solid tumors immunosuppression cell therapy Medicine (General) R5-920 Hawkins ER D'Souza RR Klampatsa A Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
description	Elizabeth R Hawkins, Reena R D’Souza, Astero Klampatsa Division of Cancer Therapeutics, The Institute of Cancer Research, London, UKCorrespondence: Astero KlampatsaThoracic Oncology Immunotherapy Group, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UKTel +44 208 722 4090Email astero.klampatsa@icr.ac.ukAbstract: Chimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic receptor which redirects effector function to the tumor, to improve efficacy and reduce toxicities associated with conventional treatments, such as radiotherapy and chemotherapy. This approach has proved effective in treating hematological malignancies; however, the same effects have not been observed in solid tumors. The immunosuppressive tumor microenvironment (TME) creates a significant barrier to solid tumor efficacy and reduces the anti-cancer activity of endogenous tumor-resident immune cells, enabling cancer progression. In recent years, researchers have attempted to enhance CAR T-cell function in the TME by engineering the cells to express various proteins alongside the CAR. Examples of this engineering include inducing CAR T-cells to secrete cytokines or express cytokine receptors to modulate the cytokine milieu of the TME. Alternatively, the CAR T-cell may secrete antibody-like proteins to target a range of tumor antigens. Collectively, these methods are termed armored CAR T-cell therapy, and in this review, we will discuss the range of armored CAR T-cell approaches which have been investigated to date.Keywords: armored CAR T-cells, immunotherapy, tumor microenvironment, solid tumors, immunosuppression, cell therapy
format	article
author	Hawkins ER D'Souza RR Klampatsa A
author_facet	Hawkins ER D'Souza RR Klampatsa A
author_sort	Hawkins ER
title	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
title_short	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
title_full	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
title_fullStr	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
title_full_unstemmed	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
title_sort	armored car t-cells: the next chapter in t-cell cancer immunotherapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ebb64adc425b40b8aba3cb8d1d89150f
work_keys_str_mv	AT hawkinser armoredcartcellsthenextchapterintcellcancerimmunotherapy AT dsouzarr armoredcartcellsthenextchapterintcellcancerimmunotherapy AT klampatsaa armoredcartcellsthenextchapterintcellcancerimmunotherapy
_version_	1718390746595196928

Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy

Ejemplares similares